Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors

Journal Article · Sat Oct 01 00:00:00 EDT 1988 · Am. J. Obstet. Gynecol.; (United States)

DOI:https://doi.org/10.1016/S0002-9378(88)80150-9· OSTI ID:6866394

Haisma, H J; Moseley, K R; Battaile, A; Griffiths, T C; Knapp, R C

Radiolabeled monoclonal antibodies may be useful for radioimmunotherapy of gynecologic tumors. Iodine 131-labeled F(ab')2 fragments of a monoclonal antibody, OC 125, with specificity for ovarian carcinoma, were used to study the distribution and pharmacokinetics of this antibody in patients with gynecologic tumors. The radiolabeled antibody was injected intravenously or intraperitoneally into 10 patients suspected of having ovarian cancer. Blood and urine samples were used for pharmacokinetic studies, and biopsy specimens were examined for the uptake of antibody. The serum half-life of the labeled antibody was 30 hours after intravenous administration, with 20% of the injected dose per liter detected at 24 hours. After intraperitoneal injection, the appearance of antibody in serum was slow, with a maximum level of 1.4% of the injected dose per liter at 24 hours. Urinary excretion of the radiolabeled antibody was similar for intravenous and intraperitoneal administration, with approximately 50% of the injected dose excreted after 48 hours. Intraperitoneal administration of the radiolabeled antibody resulted in a higher uptake of antibody in the tumor and a lower uptake of antibody in normal tissues. On the basis of this limited study, intraperitoneal administration of radiolabeled antibody is preferred over intravenous administration for radioimmunotherapy of ovarian cancer.

• Research Organization: Brigham and Women's Hospital, Boston, MA (USA)
• OSTI ID: 6866394
• Journal Information: Am. J. Obstet. Gynecol.; (United States), Vol. 159:4
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
MONOCLONAL ANTIBODIES
TISSUE DISTRIBUTION
NEOPLASMS
RADIOIMMUNOTHERAPY
BIOLOGICAL HALF-LIFE
INTRAPERITONEAL INJECTION
INTRAVENOUS INJECTION
IODINE 131
PATIENTS
RADIOIMMUNOASSAY
SPECIFICITY
ANTIBODIES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
DAYS LIVING RADIOISOTOPES
DISEASES
DISTRIBUTION
IMMUNOASSAY
IMMUNOLOGY
INJECTION
INTAKE
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOTOPE APPLICATIONS
ISOTOPES
MEDICINE
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
RADIOASSAY
RADIOIMMUNOLOGY
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
THERAPY
TRACER TECHNIQUES
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)
550601 - Medicine- Unsealed Radionuclides in Diagnostics